H.C. Wainwright raised the firm’s price target on Bausch + Lomb (BLCO) to $16 from $15 and keeps a Buy rating on the shares. The company reported a Q2 sales beat with Miebo posting 111% year-over-year prescription growth, the analyst tells investors in a research note. The firm points out Bausch + Lomb’s updated guidance range absorbs potential tariffs in the back half of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Reports Q2 2025 Financial Results
- Bausch + Lomb Reports Q2 2025 Revenue Growth, Raises Full-Year Guidance
- Bausch + Lomb reports Q2 adjusted EPS 7c, consensus 8c
- Bausch + Lomb raises FY25 revenue view to $5.000B-$5.1050B from $5.000B-$5.100B
- Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops